全文获取类型
收费全文 | 128781篇 |
免费 | 11268篇 |
国内免费 | 6621篇 |
专业分类
耳鼻咽喉 | 1224篇 |
儿科学 | 1958篇 |
妇产科学 | 2930篇 |
基础医学 | 13446篇 |
口腔科学 | 2677篇 |
临床医学 | 15977篇 |
内科学 | 20151篇 |
皮肤病学 | 1590篇 |
神经病学 | 6394篇 |
特种医学 | 4195篇 |
外国民族医学 | 40篇 |
外科学 | 13339篇 |
综合类 | 19308篇 |
现状与发展 | 20篇 |
一般理论 | 18篇 |
预防医学 | 9427篇 |
眼科学 | 3442篇 |
药学 | 13461篇 |
115篇 | |
中国医学 | 6538篇 |
肿瘤学 | 10420篇 |
出版年
2024年 | 345篇 |
2023年 | 1716篇 |
2022年 | 4017篇 |
2021年 | 5438篇 |
2020年 | 4054篇 |
2019年 | 3666篇 |
2018年 | 3940篇 |
2017年 | 3705篇 |
2016年 | 3308篇 |
2015年 | 5235篇 |
2014年 | 6733篇 |
2013年 | 6945篇 |
2012年 | 10123篇 |
2011年 | 10871篇 |
2010年 | 7481篇 |
2009年 | 6150篇 |
2008年 | 7783篇 |
2007年 | 7725篇 |
2006年 | 7317篇 |
2005年 | 6688篇 |
2004年 | 4839篇 |
2003年 | 4400篇 |
2002年 | 3650篇 |
2001年 | 3090篇 |
2000年 | 2847篇 |
1999年 | 2643篇 |
1998年 | 1311篇 |
1997年 | 1220篇 |
1996年 | 986篇 |
1995年 | 948篇 |
1994年 | 885篇 |
1993年 | 504篇 |
1992年 | 889篇 |
1991年 | 801篇 |
1990年 | 668篇 |
1989年 | 569篇 |
1988年 | 525篇 |
1987年 | 450篇 |
1986年 | 357篇 |
1985年 | 284篇 |
1984年 | 184篇 |
1983年 | 167篇 |
1982年 | 95篇 |
1981年 | 93篇 |
1979年 | 140篇 |
1978年 | 111篇 |
1977年 | 83篇 |
1974年 | 94篇 |
1973年 | 72篇 |
1972年 | 87篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
1.
2.
Gui-Qi Zhu Ke-Qing Shi Sha Huang Gui-Qian Huang Yi-Qian Lin Zhi-Rui Zhou Martin Braddock Yong-Ping Chen Ming-Hua Zheng 《Medicine》2015,94(11)
Major ursodeoxycholic acid (UDCA)-based therapies for primary biliary cirrhosis (PBC) include UDCA only, or combined with either methotrexate (MTX), corticosteroids (COT), colchicine (COC), or bezafibrate (BEF). As the optimum treatment regimen is unclear and warrants exploration, we aimed to compare these therapies in terms of patient mortality or liver transplantation (MOLT) and adverse events (AE).PubMed, the Cochrane Library, and Scopus were searched for randomized controlled trials up to August 31, 2014. We estimated the hazard ratios (HRs) for MOLT and odds ratios (ORs) for AE. A sensitivity analysis based on the dose of UDCA was also executed.Thirty-one eligible articles were included. Compared with COT plus UDCA, UDCA (HR 0.38, 95% confidence interval [CI] 0.09–1.39), BEF plus UDCA (HR 0.29, 95% CI 0.02–4.83), COC plus UDCA (HR 0.39, 95% CI 0.07–2.25), MTX plus UDCA (HR 0.28, 95% CI 0.05–1.63), or OBS (HR 0.49, 95% CI 0.11–2.01) all provided an increased risk of MOLT. With respect to drug AE profile, although not differing appreciably, BEF plus UDCA was associated with more AEs compared with UDCA (OR 3.16, 95% CI 0.59–20.67), COT plus UDCA (OR 2.27, 95% CI 0.15–33.36), COC plus UDCA (OR 1.00, 95% CI 0.09–12.16), MTX plus UDCA (OR 2.03, 95% CI 0.23–17.82), or OBS (OR 3.00, 95% CI 0.53–20.75). The results of sensitivity analyses were highly consistent with previous analyses.COT plus UDCA was the optimal UDCA-based regimen for both MOLT and AEs. BEF plus UDCA was most likely to cause AEs, whereas monotherapy with UDCA and coadministriation of COT plus UDCA appeared to be associated with the fewest AEs for PBC treatment. 相似文献
3.
4.
5.
6.
It is hypothesized that persons who use drugs (PWUD) in Vietnam who are also HIV-positive may face additional challenges in psychosocial outcomes, and these challenges may extend to their family members. In this study, we examined depressive symptoms, stigma, social support, and caregiver burden of HIV-positive PWUD and their family members, compared to the outcomes of HIV-negative PWUD and their family members. Baseline, 3-month, and 6-month assessment data were gathered from 83 PWUD and 83 family members recruited from four communes in Phú Th? Province, Vietnam. For PWUD, although we observed a general decline in overall stigma over time for both groups, HIV-positive PWUD consistently reported significantly higher overall stigma for all three periods. Depressive symptoms among family members in both groups declined over time; however, family members of HIV-positive PWUD reported higher depressive symptoms across all three periods. In addition, family members of HIV-positive PWUD reported lower levels of tangible support across all three periods. Caregiver burden among family members of HIV-positive PWUD increased significantly over time, whereas the reported burden among family members of HIV-negative PWUD remained relatively unchanged. The findings highlight the need for future interventions for PWUD and family members, with targeted and culturally specific strategies to focus on the importance of addressing additional stigma experienced by PWUD who are HIV-positive. Such challenges may have direct negative impact on their family members' depressive symptoms, tangible support, and caregiver burden. 相似文献
7.
9.
目的:探讨美托洛尔(β1受体阻滞剂)用于老年COPD合并冠心病史治疗的临床疗效。方法:选取2018年6月—2019年6月在我院接受治疗的60岁以上(包括60岁)COPD合并冠心病史老年患者,分为对照组与观察组。对照组给予接受布地奈德福莫特罗粉吸入剂治疗,观察组在使用布地奈德福莫特罗粉吸入剂治疗的基础上口服琥珀酸美托洛尔缓释片治疗,观察对比两组治疗效果。结果:观察组临床治疗效果优于对照组,观察组住院时长以及并发症的发生率低于对照组(P<0.05),差异具有统计学意义。结论:老年COPD合并冠心病史接受美托洛尔治疗,可有效缩短住院时长、用药效果明显、有效提升用药安全性,值得临床推广。 相似文献
10.